19 March 2024
ImmuPharma
PLC
("ImmuPharma" or the "Company")
Grant of
Share Options
ImmuPharma PLC (LSE:IMM), the
specialist drug discovery and development company, announces the
grant of share options as follows.
The Remuneration Committee
(comprising the Non-Executive Directors) has determined that the
following unapproved Share Options have been awarded to the
Executive Directors with vesting conditions which reflect the
corporate objective of restoring and enhancing shareholder value as
follows:
Tim
McCarthy
8,000,000 share options (exercise price £0.02)
Tim Franklin
6,500,000
share options (exercise price £0.02)
Sebastien Goudreau
5,000,000 share options (exercise price
£0.02)
In addition, 5,500,000 unapproved
Share Options have been awarded to other
employees/contractors with the same performance
conditions.
Share Option Period: All Share
Options are valid for 10 years from the date of issue.
Time and Performance
Conditions:
All Share Options will vest at the
latter of:
·
When the Company has completed a new commercial deal of
significant value; and
· 3
years from the date of issue
The Remuneration Committee will
determine when these conditions have been met.
ENDS
|
For further information please
contact:
|
ImmuPharma PLC (www.immupharma.com)
Tim McCarthy, Chief Executive
Officer
Lisa Baderoon, Head of Investor
Relations
|
+44 (0) 207 206 2650
+ 44 (0) 7721 413496
|
|
|
|
|
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
Stanford Capital Partners (Joint Broker)
Patrick Claridge, Bob
Pountney
SI
Capital (Joint Broker)
Nick Emerson
|
+44 (0) 203
368
3550
+44 (0) 203 650 3650
+44 (0) 1483 413500
|
|
|
|
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a
specialty biopharmaceutical company that discovers and develops
peptide-based therapeutics. The Company's portfolio includes novel
peptide therapeutics for autoimmune diseases and anti-infectives.
The lead program, Lupuzor™, is a first-in class autophagy
immunomodulator for the treatment of Lupus and preclinical analysis
suggest therapeutic activity for many other autoimmune diseases
that share the same autophagy mechanism of action.
For additional information about
ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity
Identifier) code : 213800VZKGHXC7VUS895.
Notification and public disclosure
of transactions by persons discharging managerial responsibilities
and persons closely associated with them.
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Tim
McCarthy
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
Chairman and Chief Executive Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission
allowance market participant, auction platform, auctioneer or
auction monitor
|
|
a)
|
Name
|
ImmuPharma PLC
|
|
b)
|
LEI
|
213800VZKGHXC7VUS895
|
|
4
|
Details of the transaction(s):
section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of 1p each
ISIN: GB0033711010
|
|
b)
|
Nature of the transaction
|
Grant of share options over new Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
Exercise
Price
|
Volume
|
|
2
pence
|
8,000,000
|
|
|
|
|
|
|
d)
|
Aggregated information
- Aggregated
volume
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
18
March 2024
|
|
f)
|
Place of the transaction
|
n/a
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Tim
Franklin
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
Chief Operating Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission
allowance market participant, auction platform, auctioneer or
auction monitor
|
|
a)
|
Name
|
ImmuPharma PLC
|
|
b)
|
LEI
|
213800VZKGHXC7VUS895
|
|
4
|
Details of the transaction(s):
section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of 1p each
ISIN: GB0033711010
|
|
b)
|
Nature of the transaction
|
Grant of share options over new Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
Exercise
Price
|
Volume
|
|
2
pence
|
6,500,000
|
|
|
|
|
|
|
d)
|
Aggregated information
- Aggregated
volume
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
18
March 2024
|
|
f)
|
Place of the transaction
|
n/a
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Sebastien Goudreau
|
|
2
|
Reason for the
notification
|
|
a)
|
Position/status
|
Director
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission
allowance market participant, auction platform, auctioneer or
auction monitor
|
|
a)
|
Name
|
ImmuPharma PLC
|
|
b)
|
LEI
|
213800VZKGHXC7VUS895
|
|
4
|
Details of the transaction(s):
section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where
transactions have been conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of 1p each
ISIN: GB0033711010
|
|
b)
|
Nature of the transaction
|
Grant of share options over new Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
Exercise
Price
|
Volume
|
|
2
pence
|
5,000,000
|
|
|
|
|
|
|
d)
|
Aggregated information
- Aggregated
volume
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
18
March 2024
|
|
f)
|
Place of the transaction
|
n/a
|